Your browser is no longer supported. Please, upgrade your browser.
CTMX CytomX Therapeutics, Inc. monthly Stock Chart
CTMX [NASD]
CytomX Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.17 Insider Own0.20% Shs Outstand46.20M Perf Week0.54%
Market Cap339.69M Forward P/E- EPS next Y-2.20 Insider Trans0.00% Shs Float42.34M Perf Month13.20%
Income-53.60M PEG- EPS next Q-0.50 Inst Own80.80% Short Float8.66% Perf Quarter3.20%
Sales92.30M P/S3.68 EPS this Y-11.10% Inst Trans-4.19% Short Ratio8.84 Perf Half Y-9.01%
Book/sh1.04 P/B7.13 EPS next Y-141.80% ROA-13.80% Target Price12.56 Perf Year16.94%
Cash/sh7.01 P/C1.06 EPS next 5Y-0.90% ROE-94.20% 52W Range3.60 - 15.44 Perf YTD-10.71%
Dividend- P/FCF- EPS past 5Y-17.70% ROI-216.20% 52W High-52.72% Beta0.73
Dividend %- Quick Ratio3.30 Sales past 5Y62.50% Gross Margin- 52W Low103.06% ATR0.33
Employees158 Current Ratio3.30 Sales Q/Q66.40% Oper. Margin-77.10% RSI (14)52.92 Volatility3.64% 5.17%
OptionableYes Debt/Eq0.00 EPS Q/Q39.00% Profit Margin-58.10% Rel Volume1.27 Prev Close7.42
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume414.55K Price7.30
Recom2.30 SMA20-0.50% SMA504.63% SMA200-5.84% Volume95,249 Change-1.62%
Sep-22-20Downgrade Guggenheim Buy → Neutral
Jun-01-20Downgrade Jefferies Buy → Hold $16 → $10
May-14-20Reiterated H.C. Wainwright Buy $16 → $12
Mar-24-20Upgrade Wedbush Neutral → Outperform
Mar-04-20Initiated Barclays Equal Weight $7
Nov-20-19Initiated Guggenheim Buy
Nov-11-19Downgrade Wedbush Outperform → Neutral $25 → $8
Jun-13-19Initiated Mizuho Buy
May-14-19Initiated Cantor Fitzgerald Overweight $21
Mar-11-19Initiated Barclays Overweight $16
Nov-26-18Initiated Piper Jaffray Overweight $22
Oct-15-18Initiated Goldman Neutral $21
Sep-13-18Initiated H.C. Wainwright Buy $32
Jun-01-18Initiated SunTrust Buy $38
Jan-05-18Initiated Citigroup Buy $40
Sep-08-17Initiated Wedbush Outperform $26
Mar-27-17Initiated H.C. Wainwright Buy $24
Mar-02-17Initiated Instinet Buy $21
Jan-03-17Downgrade Oppenheimer Outperform → Perform
Nov-02-15Initiated Oppenheimer Outperform $17
Dec-03-20 08:00AM  
Nov-11-20 04:01PM  
Nov-07-20 08:40AM  
Nov-06-20 03:01PM  
Nov-05-20 08:00PM  
04:15PM  
04:15PM  
08:00AM  
Oct-29-20 12:34PM  
08:00AM  
Oct-09-20 08:32AM  
Oct-06-20 05:41PM  
04:10PM  
Sep-18-20 08:00AM  
Sep-02-20 08:00AM  
Aug-24-20 09:23AM  
Aug-06-20 04:15PM  
Aug-04-20 08:00AM  
Jul-30-20 12:33PM  
Jul-28-20 08:00AM  
Jul-20-20 04:03PM  
01:00PM  
12:40PM  
11:40AM  
11:00AM  
09:48AM  
08:50AM  
07:30AM  
06:20AM  
12:20AM  
Jul-18-20 03:45PM  
01:35PM  
Jul-17-20 11:24PM  
01:30PM  
01:00PM  
12:32PM  
11:50AM  
11:21AM  
Jul-16-20 03:45PM  
01:55PM  
01:53PM  
12:12PM  
12:10PM  
11:30AM  
10:11AM  
09:52AM  
09:39AM  
08:00AM  
Jul-15-20 09:55AM  
09:25AM  
Jul-14-20 12:23PM  
11:00AM  
10:24AM  
09:24AM  
03:49AM  
Jul-13-20 10:15AM  
09:50AM  
01:30AM  
Jul-12-20 11:00AM  
Jul-10-20 11:47PM  
06:57PM  
05:30PM  
01:30PM  
01:00PM  
11:34AM  
Jul-09-20 04:20PM  
03:15PM  
Jul-08-20 06:50PM  
01:50PM  
01:15PM  
01:10PM  
Jul-07-20 05:30PM  
04:51PM  
Jul-06-20 11:00PM  
09:10PM  
01:40PM  
12:58PM  
01:30AM  
Jul-03-20 02:55PM  
11:19AM  
Jul-02-20 10:10PM  
09:40PM  
04:45PM  
03:24PM  
Jul-01-20 07:20PM  
06:32PM  
03:30PM  
03:00PM  
11:00AM  
10:18AM  
Jun-30-20 09:30PM  
08:20PM  
01:40PM  
01:00PM  
Jun-29-20 01:25PM  
10:59AM  
08:45AM  
07:45AM  
01:30AM  
Jun-27-20 09:24AM  
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.President and CEOSep 21Option Exercise6.6120,500135,601105,964Sep 23 04:53 PM
McCarthy Sean A.President and CEOMay 12Option Exercise1.1336,00040,820120,306May 14 04:31 PM
McCarthy Sean A.President and CEOMay 12Sale15.0036,000540,00084,306May 14 04:31 PM